Latest News:

Cholangiocarcinoma Foundation Australia Partners with Genomic Focus

The Basics difference between Gem/Cis with Durvalumab vs. Keytruda

PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia

Steven West: Cholangio Survivor

Karen O’Hagan-Humphries: Cholangio Survivor

Lynette Williams: Cholangio Survivor

Lisa Salem-Craine: Cholangio Survivor

Latest:

Cholangiocarcinoma Foundation Australia Partners with Genomic Focus

The Basics difference between Gem/Cis with Durvalumab vs. Keytruda

PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia

Steven West: Cholangio Survivor

Karen O’Hagan-Humphries: Cholangio Survivor

Lynette Williams: Cholangio Survivor

Lisa Salem-Craine: Cholangio Survivor

Medical advances improve Cholangiocarcinoma outcomes

Medical advances improve Cholangiocarcinoma outcomes…

Patients with cholangiocarcinoma (bile duct cancer), show no signs of the disease early on. Bile duct cancer usually presents at an advanced stage, which carries a poor prognosis. New advances in medical treatment offer hope. Milind Javle, M.D., associate professor in Gastrointestinal Medical Oncology at MD Anderson Cancer Center, discusses new therapies for bile duct cancer, including, immunotherapy and gene mutation profiling.

Also see on Apple itunes https://itunes.apple.com/us/podcast/medical-advances-improve-bile/id431848216?i=335148996&mt=2

Shared Information improves and Galvanises our Outcomes
What do you think about this video ? can you recommend a video? We welcome your comments?

By Steve|2018-08-27T06:29:54+12:00August 27th, 2018|IMMUNOTHERAPY, TRIALS, Videos|0 Comments

About the Author: Steve

Gold Coast, Australia |>> Kiwi-born Waikanae, New Zealand |>> CEO at Cholangiocarcinoma Foundation Australia & ( NZ) |>> Founder of The Main Beach Foundation - Putting Community Responsibility back into Cancer |>> Your biggest RISK when responding to a cancer diagnosis, is not knowing what you do not know. Your biggest advantage is to begin learning from someone who does.

0 0 votes

Article Rating

Subscribe

0 Comments

Inline Feedbacks

View all comments

CCF Australia – Educator (2)

Who Are We

As patients, we must first understand cancer before we can control and eliminate it.

As a patient-led foundation, we specialise in offering patient-integrated support, response solutions, and strategies for those affected by Cholangiocarcinoma. We actively collaborating with scientific researchers, healthcare professionals, and industry leaders, to improve today’s patient outcomes and survival rates – Read More –

Our North Star: Empower the Patient – Increase Survival: Empower their community – Exponentially Increase Survivorship.

Our Patient-led Pillars

Empower The Patient – Increase Survival: Empower and align their supporters – Exponentially increase survival.
Better Equip and Empower: We better equip and empower the patient’s capacity to more effectively respond and survive their diagnosis. This includes aligning the supporting science, medical professionals, and industry with their individual response process.
Today’s Science For Today’s Patient Survival: Ensure today’s scientific advancements are fully utilized for today’s patient toolkit and survival.

Shaping the Future:

The Empowered Patient is uniquely positioned and equipped to understand, engage, and succeed by utilizing a process that integrates scientific advancements, evidence-based medicine, and human resilience attributes into a comprehensive response strategy.

Fully embracing the concept of an empowered patient will advance science, reshape the healthcare response, and close the unattended gap between early detection and late-stage diagnosis.

Join our updates

Copyright 2017 | All Rights Reserved | Cholangiocarcinoma Foundation Australia